Article Abstract

The state of the art in the development of a panel of biomarkers for the early detection of lung cancer

Authors: Fatemeh Rahimi Jamnani

Abstract

Lung cancer is the second most commonly diagnosed cancer in the US, with 222,500 new cases diagnosed in 2017 (1,2). Furthermore, lung cancer is the leading cause of death in both men and women with cancer, accounting for 155,870 deaths in 2017 (1 in 4 cancer deaths) (1,2). The 5-year relative survival rate for lung cancer is 15% and 21% for men and women, respectively, and for only 16% of lung cancer patients diagnosed at a localized stage, the 5-year relative survival rate is 55% (2).